Isogen, Framatome’s joint venture with Kinectrics, achieves milestones in medical isotope production in Canada

August 20, 2020 | 1 min |
Category: medical
Isogen, a joint venture that Framatome and Kinectrics launched earlier this year, recently celebrated critical milestones in its work with Bruce Power to produce lifesaving medical isotopes for use in the fight against cancer. The Isogen team is providing and supporting isotope production systems for Bruce Power’s nuclear reactors to generate Lutetium-177, a medical isotope that is used for a variety of cancer treatments.

As part of the milestone celebration, Bill Walker, Associate Energy Minister and Member of Provincial Parliament for Bruce-Grey-Owen Sound, along with representatives from Framatome, Bruce Power and Kinectrics, toured Framatome’s state-of-the-art engineering facility north of Kincardine, Ontario.

At the facility, Isogen is completing the final phase of engineering, testing and design for a mock-up of the isotope production system. Once testing and engineering are complete, the team will begin building these systems for use in Bruce Power’s reactors. Framatome’s facility will also serve as a training site for Bruce Power employees.

Isotope production is expected to begin in 2022, pending regulatory and other approvals.

> Read Bruce Power's announcement


About Framatome

Framatome is an international leader in nuclear energy recognized for its innovative solutions and value added technologies for the global nuclear fleet. With worldwide expertise and a proven track record for reliability and performance, the company designs, services and installs components, fuel, and instrumentation and control systems for nuclear power plants. Its more than 14,000 employees work every day to help Framatome’s customers supply ever cleaner, safer and more economical low-carbon energy.

Framatome is owned by the EDF Group (75.5%), Mitsubishi Heavy Industries (MHI – 19.5%) and Assystem (5%).